US 11,771,113 B2
Methods of diagnosing and treating chronic kidney disease
Vincent Biourge, Aimargues (FR); Jonathan Elliott, London (GB); Dirk Hendrik Nicolaas Van Den Broek, London (GB); Rosanne Ellen Jepson, London (GB); and Yu-Mei Chang, London (GB)
Assigned to MARS, INCORPORATED, McLean, VA (US)
Appl. No. 16/615,317
Filed by MARS, INCORPORATED, McLean, VA (US)
PCT Filed May 31, 2018, PCT No. PCT/US2018/035385
§ 371(c)(1), (2) Date Nov. 20, 2019,
PCT Pub. No. WO2018/222865, PCT Pub. Date Dec. 6, 2018.
Claims priority of provisional application 62/567,623, filed on Oct. 3, 2017.
Claims priority of provisional application 62/513,396, filed on May 31, 2017.
Prior Publication US 2020/0163363 A1, May 28, 2020
Int. Cl. A61K 33/06 (2006.01); A23K 20/24 (2016.01); A23K 50/40 (2016.01); A23K 10/00 (2016.01); G01N 33/84 (2006.01)
CPC A23K 20/24 (2016.05) [A23K 10/00 (2016.05); A23K 50/40 (2016.05); G01N 33/84 (2013.01); G01N 2800/347 (2013.01)] 15 Claims
 
1. A method of diagnosing and treating an animal at risk for chronic kidney disease (CKD), wherein the method comprises:
a. obtaining a blood sample from the animal;
b. determining an amount of magnesium in the blood sample of the animal;
c. comparing the amount of magnesium to predetermined reference values; wherein the predetermined reference values are based on average magnesium levels in blood in a control population;
d. diagnosing the animal as being at risk for the CKD if the amount of magnesium is below a first predetermined value or above a second predetermined reference value; and
e. providing the animal with a treatment regimen if the amount of magnesium is below a first predetermined value or above a second predetermined reference value, wherein the treatment regimen comprises:
(i) at least one treatment regimen selected from the group consisting of administering a composition comprising an effective amount of magnesium or a salt thereof, reducing phosphate intake, reducing protein intake, administering polyunsaturated fatty acids, administering a phosphate binder therapy, administering potassium, reducing dietary sodium intake, and combinations thereof, or
(ii) at least one treatment regimen selected from the group consisting of a dietary therapy, hemodialysis, renal replacement therapy, withdrawal of kidney damaging compounds, kidney transplantation, delaying or avoiding kidney damaging procedures, modifying diuretic administration, and combinations thereof.